` TNDM (Tandem Diabetes Care Inc) vs S&P 500 Comparison - Alpha Spread

TNDM
vs
S&P 500

Over the past 12 months, TNDM has underperformed S&P 500, delivering a return of -43% compared to the S&P 500's 10% growth.

Stocks Performance
TNDM vs S&P 500

Loading

Performance Gap
TNDM vs S&P 500

Loading
TNDM
S&P 500
Difference

Performance By Year
TNDM vs S&P 500

Loading
TNDM
S&P 500
Add Stock

Competitors Performance
Tandem Diabetes Care Inc vs Peers

Tandem Diabetes Care Inc
Glance View

Market Cap
1.3B USD
Industry
Health Care

Tandem Diabetes Care Inc., a prominent figure in the healthcare sector, has carved out a notable niche with its innovative diabetes management solutions. Founded in 2006 and headquartered in San Diego, California, the company has become a leader in providing advanced insulin pump technologies. Central to Tandem’s business model is their flagship product, the t:slim X2 Insulin Pump, a sleek and user-friendly device praised for its ease of use and functionality. Through meticulous engineering and design, Tandem has positioned itself at the forefront of modern diabetes management by enhancing user experience and integrating advanced technologies such as continuous glucose monitoring (CGM) compatibility, making diabetes care more dynamic and responsive. Revenue for Tandem Diabetes Care primarily flows from the sale of these insulin pumps, along with associated supplies and accessories, which are crucial for ongoing diabetes management. The company also generates income through software and technology upgrades. By offering a subscription-based model, Tandem ensures steady revenue from the continual acquisition of consumables and technology updates, fostering customer loyalty and long-term engagement. Their commitment to innovation and patient-centric solutions has not only allowed them to tap into a growing market of diabetes patients seeking improved quality of life but has also strengthened their competitive edge in a rapidly evolving healthcare landscape.

TNDM Intrinsic Value
24.02 USD
Undervaluation 21%
Intrinsic Value
Price
Back to Top